HomeCompareFRN vs ARCC

FRN vs ARCC: Dividend Comparison 2026

FRN yields 14.01% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRN wins by $25.7K in total portfolio value
10 years
FRN
FRN
● Live price
14.01%
Share price
$14.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50.2K
Annual income
$3,336.31
Full FRN calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — FRN vs ARCC

📍 FRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRNARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRN + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRN pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRN
Annual income on $10K today (after 15% tax)
$1,190.48/yr
After 10yr DRIP, annual income (after tax)
$2,835.86/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, FRN beats the other by $2,834.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRN + ARCC for your $10,000?

FRN: 50%ARCC: 50%
100% ARCC50/50100% FRN
Portfolio after 10yr
$37.4K
Annual income
$1,668.73/yr
Blended yield
4.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

FRN
No analyst data
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRN buys
0
ARCC buys
0
No recent congressional trades found for FRN or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRNARCC
Forward yield14.01%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$50.2K$24.5K
Annual income after 10y$3,336.31$1.16
Total dividends collected$23.3K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: FRN vs ARCC ($10,000, DRIP)

YearFRN PortfolioFRN Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$12,101$1,400.56$11,381$541.15+$720.00FRN
2$14,531$1,583.88$12,621$284.08+$1.9KFRN
3$17,326$1,777.64$13,827$145.31+$3.5KFRN
4$20,520$1,980.87$15,062$73.43+$5.5KFRN
5$24,149$2,192.53$16,364$36.89+$7.8KFRN
6$28,251$2,411.47$17,757$18.49+$10.5KFRN
7$32,865$2,636.52$19,258$9.25+$13.6KFRN
8$38,032$2,866.48$20,880$4.63+$17.2KFRN
9$43,794$3,100.13$22,636$2.32+$21.2KFRN
10$50,196$3,336.31$24,539$1.16+$25.7KFRN

FRN vs ARCC: Complete Analysis 2026

FRNStock

The investment seeks to track the investment results (before fees and expenses) of the S&P/BNY Mellon New Frontier Index (USD) (the "underlying index"). The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is comprised of liquid American depositary receipts ("ADRs") listed on a U.S. exchange, global depositary receipts ("GDRs") traded on the London Stock Exchange, and ordinary share classes of equity securities listed on exchanges in Frontier Market countries that meet certain trading volume and free-float market capitalization criteria. The fund is non-diversified.

Full FRN Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this FRN vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRN vs SCHDFRN vs JEPIFRN vs OFRN vs KOFRN vs MAINFRN vs HTGCFRN vs GBDCFRN vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.